ssociation of Codon 72 of P53 Gene Polymorphism with Chronic Hepatitis CVirus Infection: A Case Control Study
Publish place: Journal of Cell and Molecular Research، Vol: 8، Issue: 2
Publish Year: 1395
نوع سند: مقاله ژورنالی
زبان: English
View: 428
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JCMR-8-2_001
تاریخ نمایه سازی: 2 آبان 1396
Abstract:
Single nucleotide polymorphism in codon 72 of p53 gene (Arg/Pro) changes p53 protein structure and affects itsactivities. Hepatitis C virus (HCV) is believed to induce hepatocellular carcinoma and P53 polymorphisms have beenassociated with human cancers. The aim of this study was to evaluate genetic variants of codon 72 of p53 genepolymorphism in HCV patients and its relationship with HCV infection. The study was conducted on 67 HCVpatients, who were referred to medical centers of Mashhad city, Iran, and 73 healthy people from the same region.Genotyping of codon 72 of p53 gene was performed by PCR-RFLP method. The distributions of different alleles ofp53 polymorphisms did not differ significantly between groups. The respective proportions of Proline homozygotes,heterozygotes, and Arginine homozygotes were 37.31%, 35.82%, 26.86% in patients and 39.72%, 27.39%, and32.87% in the control group respectively. However, we found no significant differenece for the allelic or genotypedistribution between cases and controls. Our results indicated no strong evidence of association of the p53polymorphism with HCV infection; however, further investigation is needed in different ethnic groups to elucidatethe role of this polymorphism in HCV infection.
Keywords:
Authors
Sina Gerayli
Department of Biology, Western University, London, Ontario, N۶A ۵B۷, Canada
Alireza Pasdar
Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Sina Rostami
The Influenza Centre, Department of Clinical Science, University of Bergen, N-۵۰۲۱Bergen, Norway
Samaneh Sepahi
Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran